NRAS has been working with NHS England, alongside other patient organisations to design resources for patients and health care professional's on the topic of the Adalimumab biosimilars being introduced into clinical practice.
We would like to capture your views on how, if you’ve been switched to a biosimilar of Humira, that process has worked and been handled.
Please help us by completing this 10-15 minute survey: bit.ly/2I1WfbX
[If you have been asked to switch from Humira but have not yet done so please come back to complete this survey after you’ve made that transition.]